Why Vivos Therapeutics (VVOS) Stock Is Down 25% Today
Vivos Therapeutics Inc (NASDAQ:VVOS) shares are trading lower by 26.1% to $3.05 during Thursday’s session after the company announced a $4.3 million registered offering of 1.36 million shares of common stock at $3.
Vivos Therapeutics Shares Drop 27% After Pricing of Common Stock Offering
Vivos Therapeutics shares dropped Thursday after the company said it is offering 1.4 million common shares at $3.15 per share in a registered direct offering. Shares were down 27% to $3.03 in recent trading after closing at $4.
Vivos Therapeutics Announces Pricing of $4.3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) in adults and moderate to severe in children),
TinyGemsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces $4.3M Registered Direct Offering
Vivos Therapeutics (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (“OSA”) in adults),
bovnews2d
Vivos Therapeutics (VVOS) Surges Following Landmark FDA Approval
Vivos Therapeutics is a pioneering medical device and technology company focused on addressing sleep-related breathing disorders (SRBDs), particularly obstructive sleep apnea (OSA). Their flagship ...
Investornewsbreaks Vivos Therapeutics Inc. (NASDAQ: VVOS) Awarded First-Ever FDA Clearance For Pediatric Treatment Of Sleep Apnea, Snoring
Vivos Therapeutics (NASDAQ: VVOS) , a leading medical-device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related ...
Benzinga.com1d
Vivos Therapeutics (NASDAQ:VVOS) Stock, Short Interest Report
Short interest in Vivos Therapeutics Inc (NASDAQ:VVOS) decreased during the last reporting period, falling from 58.82K to 56.53K. This put 2.28% of the company's publicly available shares short.
Seeking Alpha23d
VVOS Vivos Therapeutics, Inc.
The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.
Mena FN1mon
Investornewsbreaks Vivos Therapeutics Inc. (NASDAQ: VVOS) Releases Report On Q2 2024 Financial Results, Operational Update
(MENAFN- Investor Brand Network) Vivos Therapeutics (NASDAQ: VVOS) , a leading medical-device and technology company specializing in the development and commercialization of highly effective ...
Investing23d
Vivos Therapeutics Inc (VVOS)
Vivos Therapeutics, Inc. (VVOS) has signed a U.S. nationwide distribution agreement with Lincare, a leading supplier of in-home respiratory therapy products and services for ...
Yahoo Finance13d
Vivos Therapeutics, Inc. (VVOS)
*Close price adjusted for splits.**Close price adjusted for splits and dividend and/or capital gain distributions. Loading more data ...